ORIX CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,211 JPY | +0.28% |
|
+0.72% | +20.90% |
| Apr. 15 | MC Healthcare, Inc. acquired FreeIll Co., Ltd. from ORIX Corporation. | CI |
| Apr. 04 | S&P Global Ratings Cuts Orix's Rating, Outlook Remains Stable | MT |
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.17 for the current year.
- The company appears to be poorly valued given its net asset value.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Consumer Lending
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +20.90% | 24.24B | B | ||
| -5.86% | 51.37B | C+ | ||
| -4.23% | 31.37B | C+ | ||
| +61.37% | 28.64B | - | - | |
| +19.40% | 18.31B | B | ||
| +5.81% | 13.19B | C+ | ||
| +24.22% | 11.67B | B- | ||
| +14.79% | 8.19B | C | ||
| -30.05% | 7.35B | - | ||
| +35.41% | 6.44B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 8591 Stock
- Ratings ORIX Corporation